Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2012 Third Quarter Financial And Business Results
Date:8/8/2012

ALISO VIEJO, Calif., Aug. 8, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and nine months ended June 30, 2012.

Quarterly Financial Highlights

  • Gross and net NUEDEXTA® sales of $12.2 million and $10.1 million, respectively
  • Total company net revenues of $10.5 million
  • Cash, cash equivalents, and restricted investments of $84.1 million as of June 30, 2012
  • "Our fiscal third quarter results reflect another significant increase in net sales of NUEDEXTA seen in both our retail and institutional business," said Keith A. Katkin, president and CEO of Avanir. "Going forward, our commercial team will continue to drive revenue growth by increasing recognition of pseudobulbar affect and awareness of NUEDEXTA as the only FDA-approved treatment."

    Fiscal 2012 Third Quarter Results

  • Total net revenues for the quarter ended June 30, 2012 were $10.5 million, compared with $2.5 million for the comparable quarter in 2011. Total net revenues consist of NUEDEXTA revenue and royalty revenue from Abreva®.
  • Total operating expenses were $24.7 million in the third quarter of fiscal 2012, compared with $18.4 million in the comparable period in fiscal 2011.
  • Cash used in operations was $14.9 million in the third quarter of fiscal 2012.
  • Net loss for the fiscal 2012 third quarter was $15.0 million, or $0.11 per share, compared with a net loss of $16.1 million, or $0.13 per share, for the same period in fiscal 2011.
  • Nine-Month Results

  • Total net revenues for the first nine-months of fiscal 2012 totaled $27.7 million, compared with $5.7 million for the first nine-months of fiscal 2011.
  • Total operating expenses were $74.1 million in the first nine-months of fiscal 2012, compared to $48.1 million in the comparable period for fi
    '/>"/>

  • SOURCE Avanir Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
    2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
    4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
    5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
    6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    7. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
    8. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
    9. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
    10. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
    11. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... , July 30, 2015 AACC ... to the 2015 AACC Annual Meeting & Clinical ... from July 26–30. The meeting showcased revolutionary advancements ... the ability of healthcare providers to diagnose patients ... effective medical treatment. As of ...
    (Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... has appointed Francois Vieillard as Sales & Marketing Director. , With more ... Vieillard will be responsible for reinforcing Tronics’ business development activities worldwide. He brings ...
    (Date:7/30/2015)... 2015 According to a new ... Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract ... Trial), by End Users - Global Forecast to 2020", ... reach USD 2,107.99 million by 2020 from USD 1,034.93 ... Browse more than 75 ...
    (Date:7/30/2015)... KANSAS CITY, Kan. , July 30, 2015 ... PETX ), a pet therapeutics company focused on ... products for companion animals, today announced that its ... results from a dose confirmation study of AT-016, ... to Aratana for the treatment of osteoarthritis pain ...
    Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
    ... manufacture parts and assemble MOD® units, an innovative medication dispenser produced ... ... February 15, 2009 -- Zeus, Inc., a global leader in the ... new partnership with Avancen MOD Corporation. Avancen produces the MOD ...
    ... 13 On February 10, 2009, NeoStem, Inc. (NYSE ... NYSE Alternext US (the "Alternext") indicating that the Company ... Alternext Company Guide (the "Guide"), which requires a listed ... November 3, 2008, the Company had announced that it ...
    ... Feb. 13 /PRNewswire-FirstCall/ - Microbix Biosystems Inc. (TSX:MBX) ... the biopharmaceutical industry, it has maintained its focus ... of sustained profitability. The Company was announcing results ... , In a news release today, William J. ...
    Cached Biology Technology:Zeus Partners with Avancen MOD Corp. 2NeoStem Receives Notice of Noncompliance from NYSE Alternext US 2Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline 2Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline 3Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline 4
    (Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
    (Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
    (Date:7/2/2015)... 2015 Research and Markets( ... "Next Generation Biometrics Market by Application, Technology, Function & ... their offering. The next generation biometrics market ... a CAGR of 17.9% between 2015 and 2020 ... the market. Safran SA ( France ...
    Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
    ... MAIncreasing nitrogen runoff from urban and agriculture land-use is ... reducing this pollutant before it endangers delicate downstream ecosystems, ... from the MBL (Marine Biological Laboratory) Ecosystems Center. ... issue of Nature, are based on a major study ...
    ... returning to beaches will face the reality of "red tide" ... swimming and pose risks to humans and sea life. ... running through their neighborhoods play a critical role in filtering ... new study published in this week,s edition of the journal ...
    ... Healthy streams play a major role in minimizing the ... delivered downstream. This ecosystem service is valuable; excess nitrogen ... and depleting the water of oxygen. This phenomenon, also ... This week, a team of scientists that included ...
    Cached Biology News:Increasing nitrogen pollution overwhelms filtering capability of streams 2From the backyard to the ocean: New study shows streams act as key nitrogen filters 2Small streams mitigate human influence on coastal ecosystems 2
    Cytofix Buffer 100 mls...
    Perm/Wash Buffer 250 Tests...
    The BD PhosFlow Fix Buffer I can be used for the simultaneous fixation and permeabilization of cells prior to intracellular staining. Applications: Intracellular Staining (Flow) Storage Temperature:...
    Request Info...
    Biology Products: